Riesgo de acidosis láctica fatal y no fatal con el uso de metformina para la diabetes mellitus tipo 2
Characteristics of included studies Participants
COUNTRY: United States SETTING: research center Treatment N: 16 Control N: 16 AGE: 57+/-3 SEX: 63% men INCLUSION: Type 2 DM, poorly controlled EXCLUSIONS: patients not "in good health".
Interventions
TREATMENT: Metformin, dosage adjusted clinically + glipizide COMPARISON: glipizide
Outcomes
Postprandial and steady-state glucose, lipids, free fatty acids.
Notes Allocation concealment
D
Study
Johansen 1984
Methods
TRIAL DESIGN: Double-blind crossover randomised controlled trial DURATION: 8 weeks
Participants
COUNTRY: Denmark SETTING: outpatient Treatment N: 10 Control N: 10 AGE: 59 SEX: 30% men INCLUSION: Type 2 DM EXCLUSIONS: none listed
Interventions
TREATMENT: Metformin 500 mg/day + placebo/day. COMPARISON: acarbose + placebo
Outcomes
Postprandial glucose, HbA1, urinary glucose.
Notes Allocation concealment
B
Study
Johnson 1993
Methods
TRIAL DESIGN: Double-blind crossover randomised controlled trial DURATION: 3 months
Participants
COUNTRY: United Kingdom SETTING: outpatient Treatment N: 8 Control N: 12 AGE: 58+/-8 SEX: 62% men INCLUSION: Newly diagnosed obese untreated Type 2 DM EXCLUSIONS: renal or hepatic abnormalities
Interventions
TREATMENT: Metformin 0.85-2.5 g/day COMPARISON: placebo
Outcomes
Insulin sensitivity, HbA1, insulin, c-peptide, skeletal muscle biopsy, glucose synthetase activity.
Página 61
Copyright © John Wiley & Sons Ltd. Usado con permiso de John Wiley & Sons, Ltd.